
COMMITTEE SUBSTITUTE
FOR
Senate Bill No. 127



(By Senators Tomblin, Mr. President, and Sprouse,



By Request of the Executive)
____________
[Originating in the Committee on Health and Human Resources;
reported April 3, 2001.]
____________
A BILL to amend chapter five of the code of West Virginia, one
thousand nine hundred thirty-one, as amended, by adding
thereto a new article, designated article sixteen-c; and to
amend article two, chapter nine of said code by adding thereto
a new section, designated section twelve, all relating to
prescription drug cost management; definitions; authorizing
the director of the public employees insurance agency to
execute certain prescription drug purchasing agreements, to
amend existing contracts and to execute pharmacy benefit
management contracts; exempting said agreements and contracts
from certain purchasing requirements; requiring an audit and
reports; mandating certain innovation; providing for
termination of authorizations; and directing the secretary of
the department of health and human resources to seek certain
approvals.
Be it enacted by the Legislature of West Virginia:

That chapter five of the code of West Virginia, one thousand nine hundred thirty-one, as amended, be amended by adding thereto
a new article, designated article sixteen-c; and that article two,
chapter nine of said code be amended by adding thereto a new
section, designated section twelve, all to read as follows:
CHAPTER 5. GENERAL POWERS AND AUTHORITY OF THE GOVERNOR,
SECRETARY OF STATE AND ATTORNEY GENERAL; BOARD
OF PUBLIC WORKS; MISCELLANEOUS AGENCIES, COMMISSIONS,
OFFICES, PROGRAMS, ETC.
ARTICLE 16C. PRESCRIPTION DRUG COST MANAGEMENT ACT.
§5-16C-1. Legislative findings; purpose; short title.



The Legislature finds that the rapidly rising cost of
prescription drugs places an undue financial burden on the state of
West Virginia, the payor and the consumers of prescription drugs.
The purpose of this legislation is to authorize the director of the
public employees insurance agency to act on behalf of specified
agencies, programs and political subdivisions to manage the steady
increase in prescription drug costs, thus benefitting the citizens
and fiscal strength of this state. This article shall be known and
may be cited as the "Prescription Drug Cost Management Act".
§5-16C-2. Definitions.



As used in this article:



(1) "Audit" means a systematic examination and
collection of sufficient, competent evidential matter needed for an
auditor to attest to the fairness of management's assertions in the
financial statements and to evaluate whether management has
sufficiently and effectively carried out its responsibilities and
complied with applicable laws and regulations, conducted by an
independent certified public accountant in accordance with the applicable statement on standards: Provided, That the report shall
include an incurred-but-not-reported calculation, where available.



(2) "Director" means the director of the public
employees insurance agency, created under article sixteen of this
chapter.



(3) "Finance board" means the public employees insurance
agency finance board, created in section four, article sixteen of
this chapter.



(4) "Pharmacy benefit manager" means an entity that
procures prescription drugs at a negotiated rate under a contract
and which may serve as a third party prescription drug benefit
administrator.



(5) "Prescription drug purchasing agreement" means a
written agreement to pool all parties' prescription drug buying
power in order to negotiate the best possible prices and which
delegates authority to negotiate on behalf of the parties to the
director.



(6) "Prescription drugs" mean substances recognized as
drugs in the official "United State Pharmacopoeia, official
Homeopathic Pharmacopoeia of the United States or National
Formulary", or any supplement thereto, dispensed pursuant to a
prescription issued by an authorized health care practitioner, for
use in the diagnosis, cure, mitigation, treatment or prevention of
disease in a human, as well as prescription drug delivery systems,
testing kits and related supplies.
§5-16C-3. Authorization to execute prescription drug purchasing
agreements.



(a) The director is authorized to negotiate and execute, subject to the provisions of subsections (b), (c) and (d) of this
section and as permitted by applicable federal law, prescription
drug purchasing agreements with:



(1) All departments, agencies, authorities,
institutions, programs, quasi-public corporations and political
subdivisions of this state, including, but not limited to, the
children's health insurance program, the division of corrections,
the division of juvenile services, the regional jail and
correctional facility authority, the workers compensation fund,
state colleges and universities, public hospitals, state or local
institutions such as nursing homes, veterans' homes, the division
of rehabilitation, public health departments and the bureau of
medical services: Provided, That any contract or agreement executed
with or on behalf of the bureau of medical services shall contain
all necessary provisions to protect rebates paid to the bureau by
prescription drug manufacturers under the medicaid program;



(2) Governments of other states and jurisdictions, and
their individual departments, agencies, authorities, institutions,
programs, quasi-public corporations and political subdivisions; and



(3) Regional or multi-state purchasing alliances or
consortia, formed for the purpose of pooling the combined
purchasing power of the individual members in order to increase
bargaining power.



(b) The finance board shall approve each agreement
before it is executed by the director and the director may not
execute any agreement not approved by the finance board.



(c) The finance board may not approve and the director
may not execute any agreement that does not effectively and efficiently manage rising drug costs on behalf of the parties
thereto.



(d) The finance board may not approve and the director
may not execute any agreement that grants the state's credit for
the purchase of prescription drugs by any entity other than this
state.
§5-16C-4. Authorization to amend existing contracts.



The director may renegotiate and amend existing
prescription drug contracts to which the public employees insurance
agency is a party for the purpose of managing rising drug costs.
§5-16C-5. Authorization to execute pharmacy benefit management
contract.



The director may negotiate and execute pharmacy benefit
management contracts for the purpose of managing rising drug costs
for this state and all parties which have executed prescription
drug purchasing agreements with the director.
§5-16C-6. Exemption from purchasing division requirements.



The provisions of article three, chapter five-a of this
code do not apply to the agreements and contracts executed under
the provisions of this article, except that said contracts and
agreements shall be approved as to form and conformity with
applicable law by the attorney general.
§5-16C-7. Audit required; reports.



(a) The director shall cause to be conducted an audit of
any funds expended pursuant to any prescription drug purchasing
agreement or pharmacy benefit management contract executed under
the provisions of this article
for each fiscal year that such
prescription drug purchasing agreement or pharmacy benefit management contract is in effect. The director shall submit the
audit to the joint committee on government and finance upon
completion, but in no event later than the thirty-first day of
December after the end of the fiscal year subject to audit.



(b) The director shall provide written notice to the
joint committee on government and finance before executing a
prescription drug purchasing agreement or a pharmacy benefit
management contract, or amending an existing prescription drug
contract.
§5-16C-8. Mandate for innovation.



The director is authorized and directed to explore and
implement innovative strategies by which West Virginia may manage
the increasing costs of prescription drugs and increasing access to
prescription drugs for all of the state's citizens, including:



(1) Enacting fair prescription drug pricing policies;



(2) Providing for discount prices or rebate programs for
seniors and persons without prescription drug insurance;



(3) Coordinating programs offered by pharmaceutical
manufacturers that provide prescription drugs for free or at
reduced prices;



(4) Requiring prescription drug manufacturers to
disclose to the state expenditures for advertising, marketing and
promotion, as well as for provider incentives and research and
development efforts;



(5) Establishing counter-detailing programs aimed at
educating health care practitioners authorized to prescribe
prescription drugs about the relative costs and benefits of various
prescription drugs, with an emphasis on generic substitution for brand name drugs when available and appropriate; prescribing older,
less costly drugs instead of newer, more expensive drugs, when
appropriate; and prescribing lower dosages of prescription drugs,
when available and appropriate;



(6) Establishing disease state management programs aimed
at enhancing the effectiveness of treating certain diseases
identified as prevalent among this state's population with
prescription drugs;



(7) Studying the feasibility and appropriateness of
executing prescription drug purchasing agreements with large
private sector purchasers of prescription drugs and including such
private entities in pharmacy benefit management contracts:
Provided, That the director may not enter into any such agreement
or contract with a private entity without further enactment by the
Legislature specifically authorizing such a venture;



(8) Studying the feasibility and appropriateness of
authorizing the establishment of voluntary private buying clubs,
cooperatives or purchasing alliances comprised of small businesses
and or individuals for the purpose of purchasing prescription drugs
at optimal prices; and



(9) Other strategies, as permitted under state and
federal law, aimed at managing escalating prescription drug prices
and increasing affordable access to prescription drugs for all West
Virginia citizens.
§5-16-9. Termination.



The authorizations provided for in this article
terminate pursuant to the provisions of article ten, chapter four
of this code, on the first day of July, two thousand five, unless continued pursuant to the provisions of that article by legislation
enacted prior to the termination.
CHAPTER 9. HUMAN SERVICES.
ARTICLE 2. DEPARTMENT OF HEALTH AND HUMAN RESOURCES, AND OFFICE OF
COMMISSIONER OF HUMAN SERVICES; POWERS, DUTIES AND
RESPONSIBILITIES GENERALLY.
§9-2-12. Secretary to seek certain waivers, designations and
approvals.



(a) The secretary is hereby directed to request from the
appropriate federal authorities a waiver under the medicaid program
aimed at providing prescription drug coverage only to citizens of
this state who are sixty-five years of age or older whose annual
gross income does not exceed two hundred percent of the federal
poverty level.



(b) The secretary is hereby directed to request from the
appropriate federal authorities all necessary designations and
approvals in order to expand the availability of federally-
qualified health centers throughout this state in order to enhance
West Virginia citizens' access to the substantial discounts on
prescription drugs available under the federal supply schedule.
__________
FINANCE COMMITTEE AMENDMENT



On page two, by striking out everything after the enacting
section and inserting in lieu thereof the following:
CHAPTER 5. GENERAL POWERS AND AUTHORITY OF THE GOVERNOR,
SECRETARY OF STATE AND ATTORNEY GENERAL; BOARD
OF PUBLIC WORKS; MISCELLANEOUS AGENCIES, COMMISSIONS,
OFFICES, PROGRAMS, ETC.
ARTICLE 16C. PRESCRIPTION DRUG COST MANAGEMENT ACT.
§5-16C-1. Legislative findings; purpose; short title.

The Legislature finds that the rapidly rising cost of prescription drugs places an undue financial burden on the state of
West Virginia, the payor and the consumers of prescription drugs.
The purpose of this legislation is to authorize the director of the
public employees insurance agency to act on behalf of specified
agencies, programs and political subdivisions to manage the steady
increase in prescription drug costs, thus benefitting the citizens
and fiscal strength of this state. This article shall be known and
may be cited as the "Prescription Drug Cost Management Act".
§5-16C-2. Definitions.

As used in this article:

(1) "Audit" means a systematic examination and collection of
sufficient, competent evidential matter needed for an auditor to
attest to the fairness of management's assertions in the financial
statements and to evaluate whether management has sufficiently and
effectively carried out its responsibilities and complied with
applicable laws and regulations, conducted by an independent
certified public accountant in accordance with the applicable
statement on standards: Provided, That the report shall include an
incurred-but-not-reported calculation, where available.

(2) "Director" means the director of the public employees
insurance agency, created under article sixteen of this chapter.

(3) "Finance board" means the public employees insurance
agency finance board, created in section four, article sixteen of
this chapter.

(4) "Pharmacy benefit manager" means an entity that procures
prescription drugs at a negotiated rate under a contract and which
may serve as a third party prescription drug benefit administrator.

(5) "Prescription drug purchasing agreement" means a written
agreement to pool all parties' prescription drug buying power in
order to negotiate the best possible prices and which delegates
authority to negotiate on behalf of the parties to the director.

(6) "Prescription drugs" mean substances recognized as drugs
in the official "United State Pharmacopoeia, official Homeopathic
Pharmacopoeia of the United States or National Formulary", or any
supplement thereto, dispensed pursuant to a prescription issued by
an authorized health care practitioner, for use in the diagnosis,
cure, mitigation, treatment or prevention of disease in a human, as
well as prescription drug delivery systems, testing kits and
related supplies.
§5-16C-3. Authorization to execute prescription drug purchasing
agreements.

(a) The director is authorized to negotiate may and execute,
subject to the provisions of subsections (b), (c) and (d) of this
section and as permitted by applicable federal law, prescription
drug purchasing agreements with:

(1) All departments, agencies, authorities, institutions,
programs, quasi-public corporations and political subdivisions of
this state, including, but not limited to, the children's health
insurance program, the division of corrections, the division of
juvenile services, the regional jail and correctional facility
authority, the workers compensation fund, state colleges and
universities, public hospitals, state or local institutions such as
nursing homes, veterans' homes, the division of rehabilitation,
public health departments and the bureau of medical services:
Provided, That any contract or agreement executed with or on behalf of the bureau of medical services shall contain all necessary
provisions to protect rebates paid to the bureau by prescription
drug manufacturers under the medicaid program;

(2) Governments of other states and jurisdictions, and their
individual departments, agencies, authorities, institutions,
programs, quasi-public corporations and political subdivisions; and

(3) Regional or multi-state purchasing alliances or consortia,
formed for the purpose of pooling the combined purchasing power of
the individual members in order to increase bargaining power; and

(4) Arrangements with entities in the private sector,
including self-funded benefit plans, toward combined purchasing of
health care services, health care management services, pharmacy
benefits management services or pharmaceutical products.

(b) The finance board shall approve each agreement before it
is executed by the director and the director may not execute any
agreement not approved by the finance board.

(c) The finance board may not approve and the director may not
execute any agreement that does not effectively and efficiently
manage rising drug costs on behalf of the parties thereto to the
agreement.

(d) The finance board may not approve and the director may not
execute any agreement that grants the state's credit for the
purchase of prescription drugs by any entity other than this state.
§5-16C-4. Authorization to amend existing contracts.

The director may renegotiate and amend existing prescription
drug contracts to which the public employees insurance agency is a
party for the purpose of managing rising drug costs.
§5-16C-5. Authorization to execute pharmacy benefit management
contract.

The director may negotiate and execute pharmacy benefit
management contracts for the purpose of managing rising drug costs
for this state and all parties which have executed prescription
drug purchasing agreements with the director.
§5-16C-6. Exemption from purchasing division requirements.

The provisions of article three, chapter five-a of this code
do not apply to the agreements and contracts executed under the
provisions of this article, except that said the contracts and
agreements shall be approved as to form and conformity with
applicable law by the attorney general.
§5-16C-7. Audit required; reports.

(a) The director shall cause to be conducted an audit of any
funds expended pursuant to any prescription drug purchasing
agreement or pharmacy benefit management contract executed under
the provisions of this article for each fiscal year that such the
prescription drug purchasing agreement or pharmacy benefit
management contract is in effect. The director shall submit the
audit to the joint committee on government and finance upon
completion, but in no event later than the thirty-first day of
December after the end of the fiscal year subject to audit.

(b) The director shall provide written notice to the joint
committee on government and finance before executing a prescription
drug purchasing agreement or a pharmacy benefit management
contract
, or amending an existing prescription drug contract.
§5-16C-8. Mandate for innovation.

The director is authorized and directed to explore and implement innovative strategies by which West Virginia may manage
the increasing costs of prescription drugs and increasing increase
access to prescription drugs for all of the state's citizens,
including:

(1) Enacting fair prescription drug pricing policies;

(2) Providing for discount prices or rebate programs for
seniors and persons without prescription drug insurance;

(3) Coordinating programs offered by pharmaceutical
manufacturers that provide prescription drugs for free or at
reduced prices;

(4) Requiring prescription drug manufacturers to disclose to
the state expenditures for advertising, marketing and promotion, as
well as for provider incentives and research and development
efforts;

(5) Establishing counter-detailing programs aimed at educating
health care practitioners authorized to prescribe prescription
drugs about the relative costs and benefits of various prescription
drugs, with an emphasis on generic substitution for brand name
drugs when available and appropriate; prescribing older, less
costly drugs instead of newer, more expensive drugs, when
appropriate; and prescribing lower dosages of prescription drugs,
when available and appropriate;

(6) Establishing disease state management programs aimed at
enhancing the effectiveness of treating certain diseases identified
as prevalent among this state's population with prescription drugs;

(7) Studying the feasibility and appropriateness of executing
prescription drug purchasing agreements with large private sector
purchasers of prescription drugs and including such those private
entities in pharmacy benefit management contracts: Provided, That
the director may not enter into any such agreement or contract with
a private entity without further enactment by the Legislature
specifically authorizing such a the venture;

(8) Studying the feasibility and appropriateness of
authorizing the establishment of voluntary private buying clubs,
cooperatives or purchasing alliances comprised of small businesses
and or individuals for the purpose of purchasing prescription drugs
at optimal prices; and

(9) Other strategies, as permitted under state and federal
law, aimed at managing escalating prescription drug prices and
increasing affordable access to prescription drugs for all West
Virginia citizens.
§5-16-9. Termination.

The authorizations provided for in this article terminate
pursuant to the provisions of article ten, chapter four of this
code, on the first day of July, two thousand five, unless continued
pursuant to the provisions of that article by legislation enacted
prior to the termination.
CHAPTER 9. HUMAN SERVICES.
ARTICLE 2. DEPARTMENT OF HEALTH AND HUMAN RESOURCES, AND OFFICE OF
COMMISSIONER OF HUMAN SERVICES; POWERS, DUTIES AND
RESPONSIBILITIES GENERALLY.
§9-2-12. Secretary to seek certain waivers, designations and
approvals.

(a) The secretary shall request from the appropriate federal
authorities a waiver under the medicaid program aimed at providing prescription drug coverage only to citizens of this state who are
sixty-five years of age or older whose annual gross income does not
exceed one hundred fifty percent of the federal poverty level.

(b) The secretary shall request from the appropriate federal
authorities all necessary designations and approvals in order to
expand the availability of federally qualified health centers
throughout this state in order to enhance West Virginia citizens'
access to the substantial discounts on prescription drugs available
under the federal supply schedule.